Market Overview

CytRx's Reports Aldoxorubicin Data Demonstrates Advantages over Doxorubicin


Corporation (NASDAQ: CYTR) today announced compelling
preliminary data from its global Phase 2b soft tissue sarcoma trial
indicating that patients treated with aldoxorubicin had a significantly
higher OVERALL RESPONSE RATE (ORR) of 22% as compared to those
administered the widely used chemotherapeutic agent doxorubicin with an
ORR of 0%.

Additionally, aldoxorubicin compared with doxorubicin produced
statistically significant improvement in survival rates in animals with
a human model of glioblastoma (brain tumor), and showed an improved and
narrow distribution of aldoxorubicin within the human body in a
pharmacokinetics trial. Results from the glioblastoma trial and

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (CYTR)

View Comments and Join the Discussion!

Partner Center